Want to see AU:GLH full AI Analyst Report?
Top Page
Global Health Limited
(Sydney:GLH)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.05
▼(-46.67% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance (persistent losses, negative equity, and ongoing cash burn) and bearish technical conditions (trading below all major moving averages with negative momentum). Valuation further pressures the score due to a high P/E and no indicated dividend yield.
Positive Factors
Operational stabilization
The reduction in losses from the severe 2023 downturn suggests the business has achieved some operational stabilization. Although profitability remains negative, containing losses can preserve resources, improve execution discipline, and provide a base for future recovery if revenue and margins improve.
Negative Factors
Persistent unprofitability
Persistent annual losses and a negative TTM net margin show that the core business has not yet produced durable earnings. Continued unprofitability limits internal funding capacity, makes reinvestment harder, and leaves results vulnerable to further revenue or cost pressure over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational stabilization
The reduction in losses from the severe 2023 downturn suggests the business has achieved some operational stabilization. Although profitability remains negative, containing losses can preserve resources, improve execution discipline, and provide a base for future recovery if revenue and margins improve.
Read all positive factors
Global Health Limited (GLH) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.82M
Dividend Yield5.71%
Average Volume (3M)6.46K
Price to Earnings (P/E)69.9
Beta (1Y)0.26
Revenue Growth-1.84%
EPS Growth13.42%
CountryAU
Employees49
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.01
Shares Outstanding58,794,537
10 Day Avg. Volume2,557
30 Day Avg. Volume6,459
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)-0.79
Price to Sales (P/S)0.49
P/FCF Ratio-17.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Global Health Limited Business Overview & Revenue Model
Company Description
Headquartered in Melbourne, Australia, and established in 1985, Global Health Limited develops and supplies digital health solutions for the Australian healthcare sector. Their comprehensive suite of software addresses various needs, including spe...
Global Health Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.18M | 8.67M | 8.12M | 7.82M | 6.54M |
| Gross Profit | -566.58K | 2.10M | -689.94K | -2.18M | -664.00K |
| EBITDA | -1.39M | -793.08K | -1.77M | -7.19M | -1.69M |
| Net Income | -758.22K | -866.63K | -1.31M | -8.05M | -2.05M |
Balance Sheet | |||||
| Total Assets | 1.98M | 2.84M | 3.08M | 3.12M | 11.03M |
| Cash, Cash Equivalents and Short-Term Investments | 738.07K | 1.38M | 2.07M | 2.24M | 6.38M |
| Total Debt | 1.63M | 1.46M | 1.03M | 44.94K | 141.83K |
| Total Liabilities | 6.43M | 6.58M | 5.98M | 4.74M | 4.95M |
| Stockholders Equity | -4.45M | -3.73M | -2.90M | -1.62M | 6.09M |
Cash Flow | |||||
| Free Cash Flow | -207.03K | -706.63K | -1.15M | -4.36M | -2.08M |
| Operating Cash Flow | -196.27K | -706.63K | -1.13M | -3.46M | -1.18M |
| Investing Cash Flow | -10.76K | 5.00K | -17.48K | -902.77K | -778.93K |
| Financing Cash Flow | -424.65K | -10.70K | 982.56K | 240.86K | 3.50M |
Global Health Limited Technical Analysis
Negative
0.09
Price Trends
0.06
Negative
0.06
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
12.98
Positive
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GLH, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 12.98 is Positive, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GLH.
Global Health Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$12.34B | 39.38 | 6.58% | 1.70% | 4.36% | 4798.56% | |
53 Neutral | AU$1.38B | 24.43 | -264.68% | 4.08% | 16.55% | 13.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$223.47M | -13.54 | -5.34% | 2.79% | 1.84% | -178.23% | |
46 Neutral | AU$9.73M | -6.00 | -157.74% | ― | 121.40% | ― | |
41 Neutral | AU$2.82M | 69.91 | 15.07% | 5.71% | -1.84% | 13.42% |
* Healthcare Sector Average
AU:GLH
Global Health Limited
0.05
-0.09
-64.44%
AU:EPN
Epsilon Healthcare Limited
0.03
<0.01
12.50%
AU:RHC
Ramsay Health Care
53.55
20.61
62.56%
AU:PGC
Paragon Care Limited
0.13
-0.19
-59.38%
AU:REG
Regis Healthcare Ltd.
4.51
-3.27
-42.05%
AU:FCG
Freedom Care Group Holdings Limited
0.04
0.00
0.00%
Global Health Limited Corporate Events
Global Health boosts SaaS revenue and trims costs in FY2026 upgrade
Aug 27, 2026
Global Health Limited reported full-year FY2026 results showing a strategic shift toward higher-quality recurring revenue and improved profitability metrics despite remaining loss-making. Core annual recurring revenue, including expansion revenue,...
Global Health Limited Strengthens Corporate Governance Framework
Aug 27, 2026
Global Health Limited has detailed a comprehensive corporate governance framework that emphasises ethical standards, clear values and diversity across its organisation. The board’s composition and responsibilities are formally defined, with ...
Global Health Files Updated ASX Corporate Governance Statement
Aug 27, 2026
Global Health Limited has lodged its updated corporate governance statement and Appendix 4G with the ASX for the financial year ended 30 June 2026. The statement, current as of 27 August 2026, is hosted on the company’s website and has been ...
Global Health Loss Narrows but Going-Concern Doubts Persist
Aug 27, 2026
Global Health Limited reported a 1.84% decline in revenue from ordinary activities to A$7.18 million for the year ended 30 June 2026, while its net loss narrowed to A$758,220 from A$866,632 a year earlier. The company did not pay, recommend or dec...
Global Health trims cash outflows as SaaS shift and AI adoption boost efficiency
Jul 22, 2026
Global Health Limited reported a 12.6% increase in customer receipts to A$9.53 million for the 12 months to 30 June 2026, alongside a 30% reduction in operating and investing cash outflows, driven largely by staff and contractor reductions linked ...
Global Health Redeems 100,000 Convertible Notes, Trimming Debt Exposure
Jul 2, 2026
Global Health Limited has notified the market that 100,000 of its GLHAM convertible notes have ceased following repayment or redemption without conversion as of June 30, 2026. The move reduces the company’s outstanding convertible debt, simp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.